Mineralys Therapeutics
$26.11
23
-$0.50-1.89% 08:00 Today
Statistics
Day High
26.63
Day Low
26.58
52W High
47.65
52W Low
14.26
Volume
39,826
Avg. Volume
-
Mkt Cap
2.35B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.85
-2.06
-1.26
-0.47
Expected EPS
-0.5519
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-154.65MNet Income
Analyst Ratings
51.00Average Price Target
The highest estimate is 51.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MLYS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Ardelyx
ARDX
Mkt Cap1.05B
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.06B
Trevena
TRVN
Mkt Cap9,501
Akebia Therapeutics
AKBA
Mkt Cap241.86M
Amarin
AMRN
Mkt Cap297.2M
Galmed Pharmaceuticals
GLMD
Mkt Cap4.32M
About
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Show more...
CEO
Jon Congleton
Employees
76
Country
United States
ISIN
US6031701013
Listings
0 Comments
Share your thoughts
FAQ
What is Mineralys Therapeutics stock price today?▼
The current price of MLYS is $26.11 USD — it has decreased by -1.89% in the past 24 hours. Watch Mineralys Therapeutics stock price performance more closely on the chart.
What is Mineralys Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mineralys Therapeutics stocks are traded under the ticker MLYS.
Is Mineralys Therapeutics stock price growing?▼
MLYS stock has fallen by -1.63% compared to the previous week, the month change is a -1.77% fall, over the last year Mineralys Therapeutics has showed a +83.9% increase.
What is Mineralys Therapeutics market cap?▼
Today Mineralys Therapeutics has the market capitalization of 2.35B
When is the next Mineralys Therapeutics earnings date?▼
Mineralys Therapeutics is going to release the next earnings report on November 16, 2026.
What were Mineralys Therapeutics earnings last quarter?▼
MLYS earnings for the last quarter are -2.85 USD per share, whereas the estimation was -0.55 USD resulting in a -419.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mineralys Therapeutics revenue for the last year?▼
Mineralys Therapeutics revenue for the last year amounts to 0 USD.
What is Mineralys Therapeutics net income for the last year?▼
MLYS net income for the last year is -154.65M USD.
How many employees does Mineralys Therapeutics have?▼
As of August 19, 2026, the company has 76 employees.
In which sector is Mineralys Therapeutics located?▼
Mineralys Therapeutics operates in the Health & Wellness sector.
When did Mineralys Therapeutics complete a stock split?▼
Mineralys Therapeutics has not had any recent stock splits.
Where is Mineralys Therapeutics headquartered?▼
Mineralys Therapeutics is headquartered in RADNOR, United States.